141 Spam-Free Article(s) Found
Article Searches
Arris covers Ruckus opportunity, M&A prospects at investor day https://seekingalpha.com/news/3342303-arris-covers-ruckus-opportunity-m-prospects-investor-day?source=feed_news_all Mar 28, 2018 - At the Arris (ARRS -1.6%) investor day, executives explored the new addressable market open to it after its acquisition of the Ruckus Wireless business and said for M&A it would look to ways to b
JF's Core Biotech Buys #8: Taking Advantage Of Volatility And Initiating A Position In Dynavax https://seekingalpha.com/article/4158992-jfs-core-biotech-buys-8-taking-advantage-volatility-initiating-position-dynavax?source=feed_sector_healthcare Mar 26, 2018 - Weakness in the biotech sector continues to affect many of our holdings.For long term investors weakness and volatility should be seen as an opportunity to add to favorite stocks.Novocure received som
Biotechs Approaching New Waters https://seekingalpha.com/article/4157824-biotechs-approaching-new-waters?source=feed_all_articles Mar 20, 2018 - Biotechnology stocks are approaching highs achieved in 2015, as reflected by the Nasdaq Biotech Index.New scienceĀ is opening up great opportunities with boundless potential.The biotech sector also con
JF's Core Biotech Buys Edition 1 Volume 7: Updates And Taking Advantage Of Current Weakness https://seekingalpha.com/article/4157715-jfs-core-biotech-buys-edition-1-volume-7-updates-taking-advantage-current-weakness?source=feed_all_articles Mar 20, 2018 - The biotech sector has been a weak performer lately after several bits of bad news came including a clinical hold for Solid Biosciences.Hutchison China Meditech reported an encouraging update on clini
JF's Core Biotech Buys Edition 1 Volume 6: Buying Weakness In 2 Beaten Down Stocks https://seekingalpha.com/article/4155466-jfs-core-biotech-buys-edition-1-volume-6-buying-weakness-2-beaten-stocks?source=feed_all_articles Mar 12, 2018 - Although it's been a very short time, the model account is slightly outperforming the biotech sector at this point.Catalyst Tracker has been modified to be even more user-friendly.Neurocrine Bioscienc
Due Diligence Ramp-Up: Sierra Oncology's DNA Damage Gamble https://seekingalpha.com/article/4154834-due-diligence-ramp-sierra-oncologys-dna-damage-gamble?source=feed_sector_healthcare Mar 08, 2018 - Sierra Oncology is showing signs of interesting clinical development in early-stage trials.This article offers a look at what's known and unknown about Sierra, as well as key risks and strengths of th
JF's Core Biotech Buys Edition 1 Volume 5: The Importance Of Being Selective https://seekingalpha.com/article/4153602-jfs-core-biotech-buys-edition-1-volume-5-importance-selective?source=feed_all_articles Mar 06, 2018 - Performance for the model account has significantly overtaken the IBB.I discuss with readers the importance of being selective and having a thick filter when picking stocks.We are initiating positions
International Biotechnology Trust Plc Buys Nektar Therapeutics Inc, ACADIA Pharmaceuticals Inc, ... http://www.gurufocus.com/news/648641/international-biotechnology-trust-plc-buys-nektar-therapeutics-inc-acadia-pharmaceuticals-inc-exelixis-inc-sells-illumina-inc-incyte-corp-shire-plc Mar 02, 2018 - International Biotechnology Trust Plc Buys Nektar Therapeutics Inc, ACADIA Pharmaceuticals Inc, Exelixis Inc, Sells Illumina Inc, Incyte Corp, Shire PLC, Stocks: NKTR,ACAD,EXEL,SAGE,ARRY,TSRO,ALNY,PRTK,BLUE,SGMO,, release date:Mar 02, 2018
Biotech ETFs Head to Head: XBI vs. IBB. http://www.zacks.com/stock/news/294228/biotech-etfs-head-to-head-xbi-vs-ibb?cid=CS-ZC-FT-294228 Mar 01, 2018 - Head-to-head comparison of two Biotech ETFs, XBI and IBB.
JF's Core Biotech Buys Edition 1 Volume 4: Presenting Our 7th Idea And Adding To 2 Existing Positions https://seekingalpha.com/article/4150910-jfs-core-biotech-buys-edition-1-volume-4-presenting-7th-idea-adding-2-existing-positions?source=feed_all_articles Feb 26, 2018 - For those new to this series, it is a reboot back by popular request where we aid readers with a longer-term focus in building a diversified biotech portfolio.I remind readers that we are in no rush t

Pages: 123456789...15

<<<Page 4>